PSB229 is a brain-shuttled anti-pE3-Aβ antibody optimized for subcutaneous delivery, with enhanced brain exposure, rapid plaque reduction, and improved translational potential compared with conventional anti-amyloid approaches.

 

PSB229 is a differentiated brain-shuttled anti-pE3-Aβ therapeutic candidate designed for subcutaneous treatment of early Alzheimer’s disease, featuring:
• high target specificity and minimal off-target binding
• robust brain uptake in hTfR1 mice and cynomolgus monkey
• rapid plaque reduction in FAD4T mice

 

Partnering Opportunity: Sound Biologics is seeking strategic clinical development and commercialization partners to advance PSB229, additional neurology programs, and MabPair portfolio assets.